


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18381A

In Re Application Of: **Michel Xilinas, et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/717,182	November 18, 2003	Unassigned	23389	1614	5994

Title: **USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
18381A

In Re Application: **Michel Xilinas, et al.**



Application No. 10/717,182	Filing Date November 18, 2003	Examiner Unassigned	Customer No. 23389	Group Art Unit 1614	Confirmation No. 5994
--------------------------------------	---	-------------------------------	------------------------------	-------------------------------	---------------------------------

Title: **USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

December 20, 2004
(Date)

Signature of Person Mailing Correspondence

Frank S. DiGiglio

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Dated: **December 20, 2004**

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

cc: **FSD/XZ:ab**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michel Xilinas, et al.	Examiner:	Unassigned
Serial No.:	10/717,182	Art Unit:	1614
Filed:	November 18, 2003	Docket:	18381A
For:	USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE	Date:	December 20, 2004

Confirmation No.: 5994

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: December 20, 2004



Frank S. DiGiglio


Applicants are submitting copies of the listed reference numbers A01-A07, B01, B07-B09 and C01-C07.

Pursuant to 37 C.F.R. §1.98(d), copies of the listed reference numbers A08-A11 and B02-B06 are not provided, as these references were previously submitted to the Examiner in connection with the parent case, U.S. Serial Number 09/485,909, filed on October 19, 2000, issued as U.S. Patent No. 6,670,369, on December 30, 2003.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,




Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza, Ste 300
Garden City, New York 11530
(516) 742-4343

FSD/XZ:ab

Encls.: Form PTO-1449; Revocation of Prior Powers and
Appointment of New Attorneys and Certificate
Under 37 C.F.R. §3.73(b)



LIST OF REFERENCES CITED BY APPLICANTS
(Use several sheets if necessary)

ATTY DOCKET NO.
18381A

APPLICATION NO
10/717,182

APPLICANTS
Xilinas and Gerolymatos

FILING DATE
11/18/03

GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	3,651,205	03/21/72	Hunger et al.			
	A02	3,574,819	04/13/71	Gross et al.			
	A03	6,221,383	04/24/01	Miranda et al.			
	A04	6,165,500	12/26/00	Ceve			
	A05	5,656,286	08/12/97	Miranda et al.			
	A06	5,980,882	11/09/99	Eichman			
	A07	5,719,197	02/17/98	Kanios et al.			
	A08	5,091,391	02/25/92	Aizenman et al.			
	A09	5,980,914	11/09/99	Gerolymatos			
	A10	5,994,323	11/30/99	Gerolymatos			
	A11	6,001,852	12/14/99	Gerolymatos			
	A12	US2003/0055078A1	3/20/03	Xilinas et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	40311	04/30/75	Israel			x	
	B02	1,472,257	05/04/77	GB				
	B03	WO 98/06403	02/19/98	PCT				
	B04	WO 97/46526	12/11/97	PCT				
	B05	WO 98/40071	09/17/98	PCT				
	B06	613 560 B1	07/09/94	EP				
	B07	WO 01/82912	11/08/01	PCT				
	B08	WO 01/82911	11/08/01	PCT				
	B09	WO 00/40244	07/13/00	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Chaiyabutr N. et al. Urinary Bladder Effects After Oral Dosages of the Antidiarrhoeal Drug (Clioquinol/Phanquinone/Oxyphenonium Bromide) in Experimental Dogs. J Med Ass Thailand. 1985 Dec; 68(12):649-53
	C02	Bauer A.G. et al. Failure of Conventional Treatment to Prevent Relapse of Hepatic Amoebiasis. Neth J Med. 1981; 24(1):6-9
	C03	Yadava J.N. et al. Combined Action of Antiamoebic Drugs and Antibiotics on Axenically Grown Entamoeba Histolytica. Indian J Med Res. 1973 Jul; 61(7):971-5
	C04	Konzert W. [Experiences with a new combination preparation--iodochlorhydroxyquin (Vioform)+4,7-phenantroline-5,6-quinone (Entobex) in the treatment of anti-infectious dyspepsia in infants and small children] Wien Med Wochenschr. 1971

		Nov 6; 121(45):808-11 [in German with English translation]
	C05	Jarzebinski J. et al. Pharmaceutical Preparations Containing Quaternary Ammonium Salts. Acta Pol Pharm. 1988; vol. 45, issue: 4, p. 324-328 [in Polish with English summary]
	C06	de Graaff C.S. et al. A Patient With Opportunistic Infections Due to Acquired Immunodeficiency Syndrome. Ned Tijdschr Geneesk. 1984 Mar 24; 128(12):549-53 [in Dutch with English summary]
	C07	Ruggiero G. et al. Chronic Intestinal Amoebiasis: A case report. G. Mal. Infett. Parassit. (Italy) 1980, 32/5 (360-363) [in Italian with English summary]

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michel Xilinas, et al.

Examiner: Unassigned

Serial No: 10/717,182

Art Unit: 1614

Filed: November 18, 2003

Docket: 18381A

For: USE OF PHANQUINONE FOR THE TREATMENT OF
ALZHEIMER'S DISEASE

Confirmation No.: 5994

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

1. I hereby certify that Prana Biotechnology Limited is the assignee of the entire right, title and interest in the patent application identified above.

2. Panayotis N. Gerolymatos, a co-inventor has transferred his right, title and interest in and to the subject matter of the above-identified application by Assignment dated October 17, 2000 to P.N. Gerolymatos S.A. The Assignment was recorded on November 3, 2000 in the United States Patent and Trademark Office under Reel 011276 and Frame 0050. Michel Xilinas, the other inventor has transferred his right, title and interest in and to the subject matter of the above-identified application by Assignment dated October 19, 2000 to P.N. Gerolymatos S.A. The Assignment was recorded on November 3, 2000 in the United States Patent and Trademark Office under Reel 011275 and Frame 0991. P.N. Gerolymatos S.A. has transferred its right, title and interest in and to the subject matter of the above-identified application by Assignment dated August 9, 2004 to Prana Biotechnology Limited. The Assignment was

recorded on November 3, 2004 in the United States Patent and Trademark Office under Reel 015328 and Frame 0804.

3. The undersigned has reviewed all the documents in the chain of title of the patent applications identified above and, to the best of undersigned's knowledge and belief, Prana Biotechnology Limited has title in and to the above-identified application.

4. The undersigned is authorized to act on behalf of the assignee.

November 16, 2004
Dated

Jim V. Blinn
(Name)

CEO
(Title)